The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Bisphosphonates for the relief of pain secondary to bone metastases
Open accessAbstract
BACKGROUND: Bisphosphonates form part of standard therapy for hypercalcemia and the prevention of skeletal events in some cancers. However, the role of bisphosphonates in pain relief for bony metastases remains uncertain. OBJECTIVES: To determine the effectiveness of bisphosphonates for the relief of pain from bone metastases. SEARCH STRATEGY: MEDLINE (1966-1999), EMBASE (1980-1999), CancerLit (1966-1999), the Cochrane library (Issue 1, 2000) and the Oxford Pain Database were searched using the strategy devised by the Cochrane Pain, Palliative and Supportive Care Group with additional terms 'diphosphonate', 'bisphosphonate', 'multiple myeloma' and 'bone neoplasms'. (Last search: January 2000). SELECTION CRITERIA: Randomized trials of bisphosphonates compared with open, blinded, or different doses/types of bisphosphonates in cancer patients were included where pain and/or analgesic consumption were outcome measures. Studies where pain was reported only by observers were excluded. DATA COLLECTION AND ANALYSIS: Article eligibility, quality assessment and data extraction were undertaken by both reviewers. The proportions of patients with pain relief at 4, 8 and 12 weeks were assessed. The proportion of patients with analgesic reduction, the mean pain score, mean analgesic consumption, adverse drug reactions, and quality of life data were compared as secondary outcomes. MAIN RESULTS: Thirty randomized controlled studies (21 blinded, four open and five active control) with a total of 3682 subjects were included. For each outcome, there were few studies with available data. For the proportion of patients with pain relief (eight studies) pooled data showed benefits for the treatment group, with an NNT at 4 weeks of 11[95% CI 6-36] and at 12 weeks of 7 [95% CI 5-12]. In terms of adverse drug reactions, the NNH was 16 [95% CI 12-27] for discontinuation of therapy. Nausea and vomiting were reported in 24 studies with a non-significant trend for greater risk in the treatment group. One study showed a small improvement in quality of life for the treatment group at 4 weeks. The small number of studies in each subgroup with relevant data limited our ability to explore the most effective bisphosphonates and their relative effectiveness for different primary neoplasms. REVIEWER'S CONCLUSIONS: There is evidence to support the effectiveness of bisphosphonates in providing some pain relief for bone metastases. There is insufficient evidence to recommend bisphosphonates for immediate effect; as first line therapy; to define the most effective bisphosphonates or their relative effectiveness for different primary neoplasms. Bisphosphonates should be considered where analgesics and/or radiotherapy are inadequate for the management of painful bone metastases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Dong, Y., Hao, L., Shi, Z., Wang, G., Zhang, Z., & Han, C. (2013) · Urologia Internationalis · doi:10.1159/000351405 · Cited by 4,540
Systematic Reviews: Identifying relevant studies for systematic reviews
Dickersin, K., Scherer, R., & Lefebvre, C. (1994) · BMJ · doi:10.1136/bmj.309.6964.1286 · Cited by 2,256
WHO Handbook for Reporting Results of Cancer Treatment
Palmer, M. K. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.83 · Cited by 2,198
Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M. J., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602223340802 · Cited by 1,081
WHO handbook for reporting results of cancer treatment
Sylvester, R. (1980) · Controlled Clinical Trials · doi:10.1016/0197-2456(80)90009-4 · Cited by 1,055
Hortobagyi, G. N., Theriault, R. L., Porter, L., Blayney, D., Lipton, A., Sinoff, C., Wheeler, H., Simeone, J. F., Seaman, J., Knight, R. D., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612123352401 · Cited by 1,026
Malignant bone pain: pathophysiology and treatment
Mercadante, S. (1997) · Pain · doi:10.1016/s0304-3959(96)03267-8 · Cited by 861
Major, P., Lortholary, A., Hon, J., Abdi, E., Mills, G., Menssen, H. D., Yunus, F., Bell, R., Body, J., Quebe-Fehling, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.558 · Cited by 858
Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment
Diel, I. J., Solomayer, E.-F., Costa, S. D., Gollan, C., Goerner, R., Wallwiener, D., Kaufmann, M., & Bastert, G. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808063390601 · Cited by 809
Lipton, A., Theriault, R. L., Hortobagyi, G. N., Simeone, J., Knight, R. D., Mellars, K., Reitsma, D. J., Heffernan, M., & Seaman, J. J. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000301)88:5<1082::aid-cncr20>3.0.co;2-z · Cited by 665
Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.593 · Cited by 648
Hortobagyi, G. N., Theriault, R. L., Lipton, A., Porter, L., Blayney, D., Sinoff, C., Wheeler, H., Simeone, J. F., Seaman, J. J., Knight, R. D., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2038 · Cited by 631
Theriault, R. L., Lipton, A., Hortobagyi, G. N., Leff, R., Glück, S., Stewart, J. F., Costello, S., Kennedy, I., Simeone, J., Seaman, J. J., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.846 · Cited by 604
Paterson, A. H., Powles, T. J., Kanis, J. A., McCloskey, E., Hanson, J., & Ashley, S. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.1.59 · Cited by 557
Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma
Lahtinen, R., Laakso, M., Palva, I., Elomaa, I., & Virkkunen, P. (1992) · The Lancet · doi:10.1016/0140-6736(92)93075-x · Cited by 385
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
Body, J. J., Bartl, R., Burckhardt, P., Delmas, P. D., Diel, I. J., Fleisch, H., Kanis, J. A., Kyle, R. A., Mundy, G. R., Paterson, A. H., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3890 · Cited by 359
A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma
McCloskey, MacLennan, Drayson, Chapman, Dunn, Kanis, & Adults, F. T. M. W. P. O. L. I. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00567.x · Cited by 314
Conte, P. F., Latreille, J., Mauriac, L., Calabresi, F., Santos, R., Campos, D., Bonneterre, J., Francini, G., & Ford, J. M. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.9.2552 · Cited by 268
Clodronate decreases the frequency of skeletal metastases in women with breast cancer
Kanis, J. A., Powles, T., Paterson, A. H. G., McCloskey, E. V., & Ashley, S. (1996) · Bone · doi:10.1016/s8756-3282(96)00285-2 · Cited by 224
Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases.
Elomaa, I., Blomqvist, C., Gröhn, P., Porkka, L., Kairento, A.-L., Selander, K., Lamberg-Allardt, C., & Holmström, T. (1983) · The Lancet · doi:10.1016/s0140-6736(83)92755-1 · Cited by 209
Fulfaro, F., Casuccio, A., Ticozzi, C., & Ripamonti, C. (1998) · Pain · doi:10.1016/s0304-3959(98)00135-3 · Cited by 196
Palliative pamidronate treatment in patients with bone metastases from breast cancer.
van Holten-Verzantvoort, A. T., Kroon, H. M., Bijvoet, O. L., Cleton, F. J., Beex, L. V., Blijham, G., Hermans, J., Neijt, J. P., Papapoulos, S. E., & Sleeboom, H. P. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.491 · Cited by 196
Fitton, A., & McTavish, D. (1991) · Drugs · doi:10.2165/00003495-199141020-00009 · Cited by 187
Effects of Dichloromethylene Diphosphonate on Skeletal Mobilization of Calcium in Multiple Myeloma
Siris, E. S., Sherman, W. H., Baquiran, D. C., Schlatterer, J. P., Osserman, E. F., & Canfield, R. E. (1980) · New England Journal of Medicine · doi:10.1056/nejm198002073020602 · Cited by 185
McCloskey, E. V., Dunn, J. A., Kanis, J. A., MacLennan, I. C. M., Drayson, M. T., & the Medical Research Council Working Party on Leukaemia in Adults (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02851.x · Cited by 181
Effect of daily etidronate on the osteolysis of multiple myeloma.
Belch, A. R., Bergsagel, D. E., Wilson, K., O'Reilly, S., Wilson, J., Sutton, D., Pater, J., Johnston, D., & Zee, B. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.8.1397 · Cited by 178
Oral clodronate in breast cancer patients with bone metastases: a randomized study
Kristensen, B., Ejlertsen, B., Groenvold, M., Hein, S., Loft, H., & Mouridsen, H. T. (1999) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1999.00507.x · Cited by 176
Maxon, H. R., Schroder, L. E., Hertzberg, V., Thomas, S. R., Englaro, E., Samaratunga, R. C., Smith, H., Moulton, J. S., Williams, C. C., & Ehrhardt, G. J. (1991) · PubMed · Cited by 166
Schulz, K. F., Grimes, D. A., Altman, D. G., & Hayes, R. J. (1996) · BMJ · doi:10.1136/bmj.312.7033.742 · Cited by 163
Vinholes, J. J. F., Prakash Purohit, O., Abbey, M. E., Eastell, R., & Coleman, R. E. (1997) · Annals of Oncology · doi:10.1023/a:1008238422151 · Cited by 163
Menssen, H. D., Sakalová, A., Fontana, A., Herrmann, Z., Boewer, C., Facon, T., Lichinitser, M. R., Singer, C. R. J., Euller-Ziegler, L., Wetterwald, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.032 · Cited by 159
Powles, T. J., Ashley, S., Tidy, V. A., Nevantaus, A., McCloskey, E., Kanis, J. A., Paterson, A. H. G., & Rosenqvist, K. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.9.704 · Cited by 159
High-dose intravenous pamidronate for metastatic bone pain
Purohit, O., Anthony, C., Radstone, C., Owen, J., & Coleman, R. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.344 · Cited by 158
Ravn, P., Clemmesen, B., Riis, B. J., & Christiansen, C. (1996) · Bone · doi:10.1016/s8756-3282(96)00229-3 · Cited by 151
Markers of bone resorption in patients treated with pamidronate
Lipton, A., Demers, L., Curley, E., Chinchilli, V. M., Gaydos, L. J., Hortobágyi, G. N., Theriault, R. L., Clemens, D., Costa, L., Seaman, J. J., et al. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00277-9 · Cited by 139
Delmas, P. D., CHARHON, S. A., Chapuy, M. C., Vignon, E. P., Briançon, D., Edouard, C. M., & Meunier, P. J. (1982) · Metabolic Bone Disease and Related Research · doi:10.1016/0221-8747(82)90013-3 · Cited by 128
Bloomfield, D. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.1218 · Cited by 127
Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases.
Chapuy, M. C., Meunier, P. J., Alexandre, C. M., & Vignon, E. P. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109780 · Cited by 125
Plosker, G. L., & Goa, K. L. (1994) · Drugs · doi:10.2165/00003495-199447060-00007 · Cited by 119
A double-blind, crossover trial of intravenous clodronate in metastatic bone pain
Ernst, D. S., MacDonald, R. N., Paterson, A. H. G., Jensen, J., Brasher, P. M. A., & Bruera, E. D. (1992) · Journal of Pain and Symptom Management · doi:10.1016/0885-3924(92)90101-m · Cited by 119
Brincker, H., Westin, J., Abildgaard, N., Gimsing, P., Turesson, I., Hedenus, M., Ford, J., & Kandra, A. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00695.x · Cited by 114
Ernst, D. S., Brasher, P. M. A., Hagen, N. A., Paterson, A. H. G., MacDonald, R. N., & Bruera, E. D. (1997) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(97)00075-4 · Cited by 105
Bisphosphonates and breast carcinoma
Lipton, A. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971015)80:8+<1668::aid-cncr17>3.0.co;2-y · Cited by 104
METHODS FOR THE EARLY RECOGNITION OF COR PULMONALE
JONES, E. S., Scarrow, G. D., Sechiari, G., & Roberts, D. V. (1964) · The Lancet · doi:10.1016/s0140-6736(64)92229-9 · Cited by 101
Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study.
Robertson, A. G., Reed, N. S., & Ralston, S. H. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.9.2427 · Cited by 99
van Holten-Verzantvoort, A. T. M., Zwinderman, A. H., Aaronson, N. K., Hermans, J., van Emmerik, B., van Dam, F. S. A. M., van den Bos, B., Bijvoet, O. L. M., & Cleton, F. J. (1991) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(91)90212-v · Cited by 92
Use of bisphosphonates in cancer patients
Body, J., Coleman, R. E., & Piccart, M. J. (1996) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(96)90020-1 · Cited by 89
Coukell, A. J., & Markham, A. (1998) · Drugs & Aging · doi:10.2165/00002512-199812020-00007 · Cited by 82
Radiotherapy for painful bone metastases: A systematic review
McQuay, H. J., Carroll, D., & Moore, A. (1997) · Clinical Oncology · doi:10.1016/s0936-6555(97)80070-2 · Cited by 80
Patients' and nurses' ratings of pain and anxiety during burn wound care
van der Does, W. A. J. (1989) · Pain · doi:10.1016/0304-3959(89)90179-6 · Cited by 78
Pelger, R. C. M., Hamdy, N. A. T., Zwinderman, A. H., Nijeholt, A. A. B. L. À., & Papapoulos, S. E. (1998) · Bone · doi:10.1016/s8756-3282(97)00289-5 · Cited by 75
Gucalp, R. A., Theriault, R., Gill, I., Madajewicz, S., Chapman, R., Navari, R., Ahmann, F., Zelenakas, K., Heffernan, M., & Knight, R. D. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.1994.00420170079008 · Cited by 74
Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton
Siris, E. S., Hyman, G. A., & Canfield, R. E. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)90958-0 · Cited by 73
New approaches to pain control in patients with cancer
Ahmedzai, S. H. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00205-0 · Cited by 72
Metabolic effects of pamidronate in patients with metastatic bone disease
Vinholes, J., Guo, C., Purohit, O., Eastell, R., & Coleman, R. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.210 · Cited by 71
Terpos, E., Palermos, J., Tsionos, K., Anargyrou, K., Viniou, N. A., Papasavas, P., Meletis, J., & Yataganas, X. (2000) · European Journal Of Haematology · doi:10.1034/j.1600-0609.2000.065005331.x · Cited by 69
Merlini, G., Parrinello, G. A., Piccinini, L., Crema, F., Fiorentini, M., Riccardi, A., Pavesi, F., Novazzi, F., Silingardi, V., & Ascari, E. (1990) · Hematological Oncology · doi:10.1002/hon.2900080104 · Cited by 67
Bisphosphonates and breast carcinoma
Lipton, A. (1997) · Cancer · Cited by 63
Coleman, R., Purohit, O. P., Vinholes, J., & Zekri, J. (1997) · Cancer · Cited by 62
CRESSWELL, S. M., English, P., Hall, R. R., ROBERT, J. T., & Marsh, M. M. (1995) · British Journal of Urology · doi:10.1111/j.1464-410x.1995.tb07715.x · Cited by 61
Abildgaard, N., Rungby, J., Glerup, H., Brixen, K., Kassem, M. S., Brincker, H., Heickendorff, L., Eriksen, E. F., & Nielsen, J. (1998) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1998.tb01073.x · Cited by 59
Oral bisphosphonates in the treatment of osteoporosis: a review
Francis, R. M. (1995) · Current Therapeutic Research · doi:10.1016/0011-393x(95)85087-2 · Cited by 57
Lipton, A., Glover, D. J., Harvey, H. A., Grabelsky, S. A., Zelenakas, K., Macerata, R. S., & Seaman, J. A. (1994) · PubMed · Cited by 57
Heim, M., Clemens, M. R., Queißer, W., Pecherstorfer, M., Boewer, C., Herold, M. J., Franke, A., Herrmann, Z., Loose, R., & Edler, L. (2009) · Onkologie · doi:10.1159/000218633 · Cited by 52
Clodronate for osteolytic metastases due to breast cancer.
Elomaa, I., BLOMQVIST, C. P., Porkka, L., Holmström, T., Taube, T., Lamberg-Allardt, C. J. E., & Borgström, G. H. (1988) · PubMed · Cited by 48
Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications
Clemens, M., Fessele, K., & Heim, M. (1993) · Annals of Hematology · doi:10.1007/bf01697625 · Cited by 42
Analgesic Effect of Bisphosphonates on Bone Pain in Breast Cancer Patients a Review Article
Strang, P. M. (1996) · Acta Oncologica · doi:10.3109/02841869609083968 · Cited by 42
Coleman, R. E., Houston, S. J., Purohit, O. P., Rubens, R. D., Kandra, A., & Ford, J. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10155-1 · Cited by 41
Pamidronate treatment in patients with malignant osteolytic bone disease and pain
Koeberle, D., Bacchus, L., Thuerlimann, B., & Senn, H.-J. (1999) · Supportive Care in Cancer · doi:10.1007/s005200050218 · Cited by 40
Daragon, A., Humez, C., Michot, C., Loët, X. L., Grosbois, B., Pouyol, F., EULLER-ZIEGLER, L., Azaïs, I., Jf, B., & Ménard, J.-F. (1993) · PubMed · Cited by 38
Bisphosphonates in multiple myeloma
Berenson, J. R. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971015)80:8+<1661::aid-cncr16>3.0.co;2-y · Cited by 35
Bisphosphonates in the Treatment of Bone Diseases
Delmas, P. D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612123352409 · Cited by 33
Hultborn, R., Gundersen, S., Rydén, S., et al. (1996) · Acta Oncologica · doi:10.3109/02841869609083974 · Cited by 33
Treatment of skeletal disease in breast cancer with clodronate
Paterson, A. H. G., Ernst, D. S., Powles, T. J., Ashley, S., McCloskey, E. V., & Kanis, J. А. (1991) · Bone · doi:10.1016/8756-3282(91)90063-o · Cited by 31
Differences and similarities between patient and physician perceptions of patient pain.
Sutherland, J. E., Rm, W., Pm, C., Nesvacil, L. J., Ml, D., & Gj, G. (1988) · PubMed · Cited by 30
Bisphosphonates and bone metastases
Morton, A., & Howell, A. (1988) · British Journal of Cancer · doi:10.1038/bjc.1988.257 · Cited by 18
Tyrrell, C. T., Bruning, P. F., May-Levin, F., Rose, C., Mauriac, L., Soukop, M., & Ford, J. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)00469-6 · Cited by 17
Role of Pamidronate Disodium in the Treatment of Metastatic Bone Disease
Ripamonti, C. I., Fulfaro, F., Ticozzi, C., Casuccio, A., & Conno, F. D. (1998) · Tumori Journal · doi:10.1177/030089169808400403 · Cited by 16
Should bisphosphonates be standard therapy for bone pain?
Paterson, A. H. G. (1997) · Supportive Care in Cancer · doi:10.1007/s005200050060 · Cited by 16
The role of bisphosphonates in the treatment of bone metastases — the U.S. experience
Harvey, H. A., & Lipton, A. (1996) · Supportive Care in Cancer · doi:10.1007/bf01682343 · Cited by 15
Body, J. (1993) · Supportive Care in Cancer · doi:10.1007/bf00326636 · Cited by 14
Engler, H., Koeberle, D., Thuerlimann, B., Senn, H.-J., & Riesen, W. F. (1998) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.1998.154 · Cited by 14
Clodronate: The potential for the future
Powles, T. J. (1991) · Bone · doi:10.1016/8756-3282(91)90067-s · Cited by 14
Kraj, M. A., Pogłód, R., Pawlikowski, J., Maj, S., & Nasiłowska, B. (2000) · PubMed · Cited by 14
Tyrrell, C., Bruning, P. F., May-Levin, F., Rose, C. S., Mauriac, L., Soukoup, M., Fargeot, P., & Howell, A. (1994) · Research Explorer (The University of Manchester) · Cited by 14
The Role of Bisphosphonates for the Treatment of Bone Disease in Multiple Myeloma
Musto, P. (1998) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199809057605 · Cited by 10
The Emerging Role of Bisphosphonates in the Prevention of Bone Metastases
Paterson, A. H. G. (1999) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(98)00097-6 · Cited by 5
Disodium Pamidronate in the Treatment of Bone Metastases from Breast Cancer
Coileoni, M., Bochicchio, A. M., Nolè, F., & Bajetta, E. (1993) · Tumori Journal · doi:10.1177/030089169307900511 · Cited by 1
Berenson (2001) · doi:10.1002/1097-0142(20010401)91:7<1191::aid-cncr1119>3.0.co;2-0
Cited by
Nature and Frequency of Bisphosphonate-Associated Osteonecrosis of the Jaws in Australia
Mavrokokki, T., Cheng, A., Stein, B., & Goss, A. (2007) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2006.10.061 · Cited by 650
Bone health in cancer patients: ESMO Clinical Practice Guidelines
Coleman, R., Body, J. J., Aapro, M., Hadji, P., & Herrstedt, J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu103 · Cited by 564
Aapro, M., Abrahamsson, P. A., Body, J. J., Coleman, R. E., Colomer, R., Costa, L., Crinò, L., Dirix, L., Gnant, M., Gralow, J., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm442 · Cited by 457
Management of cancer pain: ESMO Clinical Practice Guidelines
Ripamonti, C. I., Bandieri, E., & Roila, F. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr390 · Cited by 447
Kyle, R. A., Yee, G. C., Somerfield, M. R., Flynn, P. J., Halabi, S., Jagannath, S., Orlowski, R. Z., Roodman, D. G., Twilde, P., & Anderson, K. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1269 · Cited by 409
Metadata
- Authors
- Wong, R. K., & Wiffen, P. J.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2002-04-22
- Volume
- 2017
- Issue
- 8
- Pages
- CD002068-CD002068
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1540971434
- Cited by
- 285
- References
- 92
- FWCI
- 3.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.